1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,180 | 1,200 | 18.06. | |
| 1,200 | 1,270 | 18.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo | 847 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides... ► Artikel lesen | |
| 08.06. | As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies | 683 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides... ► Artikel lesen | |
| 26.05. | In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides | 1.297 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential... ► Artikel lesen | |
| 20.05. | NANOVIRICIDES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.05. | NanoViricides Announces Closing of ~$2 Million Registered Direct Offering | 710 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 18.05. | Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides | 784 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the... ► Artikel lesen | |
| 15.05. | NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering | 541 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 15.05. | NanoViricides GAAP EPS of -$0.09 | 2 | Seeking Alpha | ||
| 15.05. | NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II | 508 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending March... ► Artikel lesen | |
| 11.05. | Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides | 667 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the... ► Artikel lesen | |
| 06.05. | D.Boral Capital: NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference | 755 | Newsfile | Shelton, Connecticut--(Newsfile Corp. - May 6, 2026) - NanoViricides, Inc. (NYSE American: NNVC), today announced its participation in the D. Boral Capital Global Conference, taking place May 7... ► Artikel lesen | |
| 04.05. | NanoViricides: NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA | 555 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 21.04. | Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides | 629 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 07.04. | Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides | 842 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 01.04. | Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides | 1.360 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to... ► Artikel lesen | |
| 11.03. | NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete | 958 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot... ► Artikel lesen | |
| 17.02. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 12.02. | MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides | 889 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the... ► Artikel lesen | |
| 10.02. | Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides | 797 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the... ► Artikel lesen | |
| 02.02. | NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres | 652 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 19,600 | -1,71 % | Formycon-Aktie: Ist sie eigentlich viel mehr wert? | Die Formycon-Aktie gehört 2026 bislang nicht zu den Börsenlieblingen. Nach einer schwachen Kursentwicklung notiert das Papier aktuell im Bereich von knapp unter 20 Euro und damit deutlich unter früheren... ► Artikel lesen | |
| RIBER | 12,840 | -0,47 % | Riber: Annual General Meeting of June 17, 2026: RIBER confirms the execution of its technology roadmap and accelerates with ROSIE | Annual General Meeting of June 17, 2026: RIBER confirms the execution of its technology roadmap and accelerates with ROSIE Bezons, June 17, 2026 - 5:45 p.m. - RIBER, the global leader in molecular... ► Artikel lesen | |
| ONTO INNOVATION | 293,40 | +0,69 % | Freedom Broker initiates Onto Innovation stock coverage with buy rating | ||
| SMOLTEK NANOTECH | 0,307 | +20,39 % | SMOLTEK NANOTECH HOLDING AB: The subscription period for Smoltek's rights issue of units begins today | ||
| VEECO INSTRUMENTS | 68,66 | -1,27 % | Veeco's new LUMINA+ MOCVD system qualified by Ennostar | ||
| SOLESENCE | 1,335 | -0,37 % | Solésence, Inc.: Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results | Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty... ► Artikel lesen | |
| KOPIN | 4,240 | -1,76 % | Fabric.AI (Nasdaq: FABC) and Kopin Corporation (Nasdaq: KOPN) Appoint Bill Maffucci to Lead Development of Neural I/o MicroLED Optical Interconnect Chip Program | NEW YORK, NY, May 06, 2026 (GLOBE NEWSWIRE) -- Fabric.AI (Nasdaq: FABC) ("Fabric.AI" or "the Company"), an AI infrastructure company developing a suite of fabless semiconductor technologies for next-generation... ► Artikel lesen | |
| NVE | 96,00 | -0,52 % | Dividendenbekanntmachungen (18.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2A SPA IT0001233417 - 0,104 EUR AIR LIQUIDE SA FR0000120073 - 3,7 EUR ALCOA CORPORATION CDIS AU0000339426 0,1 USD 0,086 EUR ALLISON... ► Artikel lesen | |
| GOMSPACE | 1,451 | +1,54 % | GomSpace Group AB: Annual general meeting held in GomSpace Group AB (publ) | Today, the annual general meeting of 2026 has been held in GomSpace Group AB (publ) (the "Company" or "GomSpace"). Below follows a summary of the decisions taken by the annual general meeting (all... ► Artikel lesen | |
| ZENTEK | 0,392 | +8,29 % | Zentek Ltd: Zentek 18-million-share private placement | ||
| GAUZY | 0,611 | -4,53 % | Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Delayed Filing of Annual Report on Form 20-F | TEL AVIV, Israel, May 26, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (NASDAQ: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that on May 19, 2026... ► Artikel lesen | |
| NANOVEU | 0,037 | -1,33 % | Daily Special: Critical Resources, Nanoveu, QMines | ||
| OBDUCAT | 0,068 | +13,04 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| ACACIA RESEARCH | 4,020 | +2,03 % | Acacia Research Q1 2026 slides show mixed results, strong liquidity | ||
| ADVANCE ZINCTEK | 0,416 | +0,97 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Mit einer aktuellen Kursveränderung von -0,080 (-6,56 %) liegt der Kurs bei 1,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.